QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform

EQS-News: QUANTRO Therapeutics GmbH / Key word(s): Miscellaneous QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform 06.08.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform

Austrian Research Promotion Agency FFG awards funding to QUANTRO, accelerating the next development phase of its transcriptomic discovery platform

Vienna (Austria), 06 August 2024: QUANTRO Therapeutics GmbH, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company received an 18-month research grant awarded by the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft, FFG) in support of a EUR 1.7 million R&D Project, catalysing the scale-up and multi-target profiling capability of QUANTRO’s technology platform to industrial level. The FFG program is financed by the Republic of Austria - specifically the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK) and the Federal Ministry of Labour and Economy (BMAW) – as well as participating federal states, companies, and research organizations.

QUANTRO’s platform is the first available, proprietary technology allowing time-resolved transcriptomic profiling, which enables the identification of modulators, activators or inhibitors of transcription factors and cell signalling regulators through the quantification of transcriptional activity with unprecedented precision and sensitivity.

QUANTRO has successfully conducted its first large screening campaigns with single and dual target assays, using its novel transcriptomic discovery platform. The funds available through the FFG grant enable the company to take the platform to a new industrial level, boosting throughput by miniaturization and automation and, most importantly, multiplexing. QUANTRO is on track to develop the first 10-target transcriptomic screens for the discovery of transcription factor targets, some of which have previously been considered “undruggable”.